- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05932212
Une étude de phase II sur AK104 pour le cancer de la vulve récurrent ou métastatique
Une étude multicentrique, ouverte, de phase II sur AK104 dans le traitement du cancer de la vulve récurrent ou métastatique
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350000
- Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510000
- Sun Yant-Sen Memorial Hospital
-
-
Hebei
-
Shijiangzhuang, Hebei, Chine, 050000
- The Fourth Hospital of Hebei Medical University
-
-
Liaoning
-
Shenyang, Liaoning, Chine, 110042
- Liaoning Cancer Hospital & Insitut
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300000
- Tianjin medical university Cancer Institut & Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310022
- Zhejiang Cancer Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Age >=18 and <=80. ECOG of 0 or 2. Life expectancy ≥ 3 months. Histologically confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy.
For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy.
At least one measurable tumor lesion per RECIST v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of childbearing potential must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of contraception
Exclusion Criteria:
Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc.
Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration.
Previous treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.).
Active or potentially recurrent autoimmune disease.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohort A: AK104
AK104 monotherapy |
AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
Autres noms:
|
|
Expérimental: Cohort B: AK104+chemotherapy
AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin) |
AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective response rate (ORR) assessed by investigator.
Délai: Up to approximately 1 years
|
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1 |
Up to approximately 1 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-free survival (PFS) Assessed by investigator
Délai: Up to approximately 2 years
|
The time from the first administration to the first documented progressive disease (PD) or death due to any cause, whichever occurs first |
Up to approximately 2 years
|
|
Duration of Response (DOR) Assessed by investigator
Délai: Up to approximately 2 years
|
Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria |
Up to approximately 2 years
|
|
Disease control rate (DCR) Assessed by investigator
Délai: Up to approximately 1 years
|
The proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥6 weeks) based on RECIST |
Up to approximately 1 years
|
|
Time to Response (TTR) Assessed by investigator
Délai: Up to approximately 1 years
|
The time from the first administration to the date of documented CR or PR |
Up to approximately 1 years
|
|
Overall survival (OS)
Délai: Up to approximately 2 years
|
The time from the first administration to death due to any cause |
Up to approximately 2 years
|
|
Adverse Events (AEs)
Délai: Up to approximately 2 years
|
Characterization of incidence, severity and abnormal clinically significant manifestation or laboratory findings. |
Up to approximately 2 years
|
|
serum concentrations of AK104
Délai: Up to approximately 2 years
|
assessment of PK include serum concentrations of AK104 at different timepoints after study drug administration |
Up to approximately 2 years
|
|
Antidrug antibodies (ADA) of AK104
Délai: Up to approximately 2 years
|
Proportion of subjects who develop detectable anti-drug antibodies (ADAs) |
Up to approximately 2 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies génitales, femme
- Tumeurs génitales, femme
- Maladies vulvaires
- Tumeurs vulvaires
- Produits chimiques organiques
- Complexes de coordination
- Carboplatine
Autres numéros d'identification d'étude
- AK104-218
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .